Patient Guide: Evaluation of 611(Recombinant Humanized Anti-interleukin-4 Receptor Alpha IgG4 Monoclonal Antibody) in Chinese Adults With Moderate to Severe Atopic Dermatitis

We'll Help You Connect with This Trial

Quri.ai is a free clinical trial matching service. We help patients like you connect directly with research sites conducting this study.

  • ✓ Get matched to the right study location for you
  • ✓ Connect directly with study coordinators at 4 participating sites
  • ✓ Understand eligibility with our simplified screening tool
  • ✓ Free service - we're here to help you access clinical research
Trial ID: NCTNCT06173284
Status: COMPLETED
Condition: Dermatitis, Atopic
Phase: PHASE3

Find a Study Location Near You

This study is available at 4 research sites. We'll help you connect with the location that's right for you.

Participating sites include:
  • • Beijing, Beijing Municipality
  • • Nanchang, Jiangxi
  • • Hangzhou, Zhejiang
  • • And 1 more locations - let us help you find the closest one

Loading interactive enrollment tools...

The full interactive experience will load momentarily

Evaluation of 611(Recombinant Humanized Anti-interleukin-4 Receptor Alpha IgG4 Monoclonal Antibody) in Chinese Adults With Moderate to Severe Atopic Dermatitis - Join Clinical Trial NCTNCT06173284

How to Join This Clinical Trial - NCTNCT06173284

Learn how to participate in this PHASE3 trial studying an investigational therapy for Dermatitis, Atopic. Current status: COMPLETED.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Dermatitis, Atopic. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
Dermatitis, Atopic
Treatment Being Tested
Investigational treatment
Study Phase
PHASE3 - Large-scale efficacy study
Enrollment Status
COMPLETED
Study Identifier
NCTNCT06173284 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 4 locations. Find a study site near you:

Clinical Research Site

Beijing, Beijing Municipality 100044 - China

Status: Contact for availability

Clinical Research Site

Nanchang, Jiangxi 330200 - China

Status: Contact for availability

Clinical Research Site

Hangzhou, Zhejiang 310003 - China

Status: Contact for availability

Clinical Research Site

Jinhua, Zhejiang 322000 - China

Status: Contact for availability

How to Enroll in This Study

To learn more about participating in this PHASE3 clinical trial for Dermatitis, Atopic:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai as Your Clinical Trial Matching Service

Quri.ai is a free clinical trial matching service that helps patients connect with research sites. We make it easier to:

  • Find clinical trials that match your condition
  • Get matched to the right study location near you
  • Connect directly with study coordinators
  • Understand if you qualify with simplified eligibility screening
  • Navigate the enrollment process with personalized support
  • Access new treatments through clinical research participation